Biofrontera Inc. (BFRI)
(Real Time Quote from BATS)
$1.67 USD
-0.02 (-1.18%)
Updated Apr 26, 2024 02:51 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Biofrontera Inc. [BFRI]
Reports for Purchase
Showing records 1 - 20 ( 58 total )
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Renegotiates Better Ameluz Terms, Ameluz sNDA PDUFA Set For 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Renegotiates Better Ameluz Terms, Adds $15.5M Cash, Ameluz sNDA PDUFA Set
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
3Q23: 25% Y/Y Revenue Growth For 2023, Cash Flow Positivity In Mid-2025
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Preannounced 3Q23 Revenue, Kept 2023 Guidance, New Ameluz Formulation
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Safety Trial With 3 Ameluz Tubes Succeeds, Expecting 2024 Label Expansion
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
2Q23: 25% YoY Revenue Growth For ''23, To Be Cash Flow Positive Around 1Q25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Pre-Releases 2Q23 Revenue Range, Developing a Low-Cost, Portable PDT Lamp
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
USPTO Issues Patent for PDT Protocol Resulting In Reduced Discomfort
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
Company: Biofrontera Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Deeper Analysis Shows 1Q23 Was Solid Revenue, Salesforce Growing
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J